Some patients who require limb salvage inflow procedures are not treatable by endovascular techniques and may not necessarily be candidates for one of the more invasive aortic procedures described above due to physiologic Regorafenib price reasons. These situations call for

a less invasive operative procedure generally consisting of an extra-anatomical bypass with or without an adjunctive endovascular procedure, the so-called “hybrid” procedure. One such procedure is the femoral-femoral bypass (FFB), which historically was thought to have early failure due to an iliac stenosis on the donor side. A recent study of 247 patients with FFB demonstrated an increased usage of Inhibitors,research,lifescience,medical adjunctive iliac percutaneous transluminal angioplasty (PTA)/stent from 0% to 54% (over a period from 1984-2010), while the rate of axillofemoral

bypass or no inflow stenting procedure decreased from 100% to 46%. Iliac PTA/stenting is associated with a decreased 5-year primary graft patency of 44% compared with 74% for axillofemoral bypass patients and 71% in patients Inhibitors,research,lifescience,medical who Inhibitors,research,lifescience,medical required no adjunctive inflow procedure. Patients with inflow iliac PTA/stents also have diminished 5-year assisted primary patency of 61% compared with 85% for axillofemoral bypass patients and 87% in patients who had no need for inflow revascularization. Five-year primary patency among claudicants and critical leg ischemia patients is similar at 65% and 68%, respectively, therefore extent of disease does not appear to impact patency.8 Passman et al. found that axillobifemoral Inhibitors,research,lifescience,medical bypasses were comparable in patency to AFB at 5 years, but since patients who receive axillobifemoral

bypasses are generally significantly more debilitated, their survival at 5 years is 45% versus 72% for ABF.9 There is a paucity of good data comparing covered versus bare expandable stents in the aortoiliac segment. The single prospective randomized controlled trial, the COBEST trail, found that lesions treated with covered stents were significantly more likely to remain free of restenosis than those treated Inhibitors,research,lifescience,medical with bare-metal stents (HR 0.35). Further subgroup analysis showed that while there was no difference and for TASC B lesions, the difference was significant for both TASC C and D lesions.10 Failed Aortoiliac Stenting Prior to embarking on endovascular interventions in the aortoiliac segments, it is imperative that the operator understands the pathophysiology and severity of inflow and/or outflow compromise. If there is inadequate flow in the infrainguinal segment, then early failure may occur. Similarly, if all proximal disease is left untreated, then the stent is more likely to be compromised. It has been shown in a 10-year follow-up that if one fails to extend treatment into the aorta for lesions that are at the aortic bifurcation, outcomes are generally inferior.